Abstract
Treatment for insomnia with melatonin (MT) in children and adolescents aged 0-17 years has doubled since 2011. The efficacy and safety profile for MT in children has not been determined. Recent clinical trials indicate, that MT only has a clinical effect on sleep latency, not on total sleep time. Furthermore, it has emerged, that proper sleep hygiene can cure the sleep problem in 50% of the children. Typically, the safety evaluation only entails an unclassified report of adverse events. Two long-term studies investigate and dispel the potential influence of MT on puberty.
MeSH terms
-
Adolescent
-
Central Nervous System Depressants / administration & dosage
-
Central Nervous System Depressants / adverse effects
-
Central Nervous System Depressants / pharmacokinetics
-
Central Nervous System Depressants / therapeutic use*
-
Child
-
Child, Preschool
-
Humans
-
Melatonin / administration & dosage
-
Melatonin / adverse effects
-
Melatonin / pharmacokinetics
-
Melatonin / therapeutic use*
-
Puberty / drug effects
-
Sleep / drug effects
-
Sleep / physiology
-
Sleep Hygiene
-
Sleep Initiation and Maintenance Disorders / drug therapy*
-
Sleep Latency / drug effects
-
Sleep Wake Disorders / drug therapy
Substances
-
Central Nervous System Depressants
-
Melatonin